The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer.
Hirotaka Iwase
Honoraria - Pfizer
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Novartis; Takeda
Yutaka Yamamoto
Research Funding - AstraZeneca; Chugai Pharma; Novartis
Takashi Ishikawa
No relevant relationships to disclose
Yasuo Hozumi
No relevant relationships to disclose
Masahiko Ikeda
No relevant relationships to disclose
Hiroji Iwata
No relevant relationships to disclose
Hiroko Yamashita
No relevant relationships to disclose
Tatsuya Toyama
No relevant relationships to disclose
Takashi Chishima
No relevant relationships to disclose
Izo Kimijima
No relevant relationships to disclose
Mutsuko Ibusuki
No relevant relationships to disclose
Shigehira Saji
No relevant relationships to disclose